GIP/GLP-1 & amylin agonists × body weight & composition

Observational studyJMIR formative research2025

Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.

Rebecca Richards et al.PubMed ↗Full text ↗Publisher ↗

  • Tirzepatidelooks good hereLower weight change, no range given.No ranges given.

What the trial testedas reported · 617 people · 2025

No range given

Reported lower weight change, no range given

−22.9kg

tirzepatide vs semaglutide

As reported

difference −22.9 kg, no interval · the paper's word: mean weight change

Who was studied, and how

617people with obesity, in this paper

The trial randomly assignedassigned by chance

tirzepatide
semaglutide

Reported lower weight change, no range given−22.9

randomised

the abstract, start to end

Mean weight change at 12 months was -22.9 kg (-22.1% of baseline weight,

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Mean weight changetirzepatide vs semaglutide
−22.9
GIP/GLP-1 & amylin agonistsBody weight & composition
1 / 4

1 paper cites it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40838489